Immunobiology Unit 15 Review: Tumor Immunology and Immunotherapy

Key Concepts in Tumor Immunology

• Tumors arise from the uncontrolled growth and division of abnormal cells due to genetic mutations and epigenetic changes
• Oncogenes are genes that, when activated or overexpressed, promote tumor growth and survival (RAS, MYC)
• Tumor suppressor genes, such as TP53 and RB1, normally regulate cell growth and division, and their inactivation contributes to tumor development
• Tumors acquire hallmark capabilities, including sustained proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis
• Tumors exhibit genetic instability and accumulate multiple mutations over time, leading to heterogeneity within the tumor
• Tumors can evade immune recognition and destruction through various mechanisms, such as downregulating antigen presentation and secreting immunosuppressive factors
• The concept of immunoediting describes the dynamic interaction between the immune system and tumors, consisting of three phases: elimination, equilibrium, and escape

Immune System's Role in Cancer

• The immune system plays a crucial role in recognizing and eliminating tumor cells through a process called immunosurveillance
  • Innate immune cells, such as natural killer (NK) cells and macrophages, can detect and kill tumor cells without prior sensitization
  • Adaptive immune responses, mediated by T cells and B cells, specifically target tumor-associated antigens (TAAs) and neoantigens
• Cytotoxic T lymphocytes (CTLs) are the primary effector cells in anti-tumor immunity, recognizing and killing tumor cells presenting specific antigens
• Helper T cells (CD4+ T cells) support the activation and function of CTLs and other immune cells through cytokine secretion and co-stimulatory signals
• Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that capture, process, and present tumor antigens to T cells, initiating adaptive immune responses
• NK cells can directly lyse tumor cells lacking MHC class I expression and secrete pro-inflammatory cytokines to enhance anti-tumor immunity
• Macrophages and neutrophils can exhibit both pro-tumor and anti-tumor functions, depending on their polarization state and the tumor microenvironment
• B cells can produce antibodies targeting tumor antigens, leading to antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)

Tumor Microenvironment

• The tumor microenvironment (TME) is a complex network of cells, soluble factors, and extracellular matrix surrounding the tumor
• TME consists of various cell types, including cancer cells, immune cells (T cells, B cells, NK cells, macrophages, DCs), fibroblasts, endothelial cells, and pericytes
• Cancer-associated fibroblasts (CAFs) support tumor growth and progression by secreting growth factors, promoting angiogenesis, and remodeling the extracellular matrix
• Tumor-associated macrophages (TAMs) can exhibit pro-tumor functions, such as promoting angiogenesis, immunosuppression, and metastasis
• Regulatory T cells (Tregs) in the TME suppress anti-tumor immune responses and maintain an immunosuppressive environment
• Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that accumulate in the TME and inhibit T cell function through various mechanisms
• The TME is characterized by hypoxia, acidosis, and nutrient deprivation, which can influence the function and survival of both cancer cells and immune cells
• Soluble factors in the TME, such as cytokines (IL-10, TGF-β), chemokines, and growth factors (VEGF), can shape the immune response and promote tumor progression

Immune Evasion Mechanisms

• Tumors employ various strategies to evade immune recognition and destruction, enabling their survival and progression
• Downregulation or loss of MHC class I molecules on tumor cells reduces antigen presentation to CTLs, making them less visible to the immune system
• Tumors can express immune checkpoint ligands, such as PD-L1 and CTLA-4, which engage inhibitory receptors on T cells and suppress their function
• Secretion of immunosuppressive cytokines (IL-10, TGF-β) by tumor cells or cells in the TME inhibits T cell activation and promotes the differentiation of Tregs
• Recruitment and expansion of immunosuppressive cell populations, such as Tregs and MDSCs, in the TME create a hostile environment for anti-tumor immune responses
• Tumor cells can express enzymes, like indoleamine 2,3-dioxygenase (IDO), which deplete essential amino acids required for T cell function and survival
• Alterations in tumor cell metabolism, such as increased glucose consumption and lactate production, can impair the function of infiltrating immune cells
• Tumor-derived exosomes containing immunosuppressive factors and miRNAs can modulate the immune response and promote tumor progression

Immunotherapy Approaches

• Immunotherapy harnesses the power of the immune system to fight cancer by enhancing, restoring, or redirecting anti-tumor immune responses
• Immune checkpoint inhibitors (ICIs) block inhibitory receptors on T cells (PD-1, CTLA-4) or their ligands on tumor cells (PD-L1), releasing the brakes on T cell activation
  • Examples of ICIs include anti-PD-1 (nivolumab, pembrolizumab), anti-PD-L1 (atezolizumab, durvalumab), and anti-CTLA-4 (ipilimumab) antibodies
• Adoptive cell therapy (ACT) involves the isolation, expansion, and reinfusion of tumor-specific T cells to boost anti-tumor immunity
  • Tumor-infiltrating lymphocytes (TILs) can be harvested from patient tumors, expanded ex vivo, and reinfused to target tumor cells
  • Chimeric antigen receptor (CAR) T cells are genetically engineered to express a synthetic receptor targeting a specific tumor antigen (CD19 for B cell malignancies)
• Cancer vaccines aim to stimulate an immune response against tumor antigens by delivering them in an immunogenic context
  • Peptide vaccines use specific tumor-associated peptides to elicit a targeted T cell response
  • Dendritic cell vaccines involve loading patient-derived DCs with tumor antigens ex vivo and reinfusing them to prime an anti-tumor immune response
• Oncolytic viruses are engineered or naturally occurring viruses that preferentially infect and lyse tumor cells, releasing tumor antigens and promoting an inflammatory response
• Cytokine therapy involves the administration of immunostimulatory cytokines, such as IL-2 and interferon-α, to enhance the activation and function of immune cells
• Combination therapies, such as combining ICIs with chemotherapy, radiation, or targeted therapies, can synergistically improve anti-tumor responses and patient outcomes

Clinical Applications and Challenges

• Immunotherapy has shown remarkable success in treating various types of cancer, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and hematological malignancies
• Response rates to immunotherapy vary among patients and cancer types, with some patients experiencing durable remissions while others show minimal benefit
• Biomarkers, such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI), can help predict patient response to immunotherapy
• Immune-related adverse events (irAEs) can occur due to the activation of the immune system, affecting various organs (skin, gastrointestinal tract, endocrine glands, lungs)
  • Management of irAEs involves close monitoring, immunosuppressive treatments (corticosteroids), and multidisciplinary care
• Resistance to immunotherapy can develop through various mechanisms, such as loss of tumor antigen expression, upregulation of alternative immune checkpoints, and acquired mutations in antigen presentation pathways
• Combining immunotherapy with other treatment modalities, such as chemotherapy, radiation, or targeted therapies, can potentially overcome resistance and improve patient outcomes
• The high cost of immunotherapies and the need for personalized approaches pose challenges for widespread implementation and access to these treatments

Emerging Trends and Future Directions

• Identifying novel immune checkpoint targets, such as LAG-3, TIM-3, and TIGIT, to develop new immunotherapeutic agents and address resistance to existing therapies
• Developing strategies to target the immunosuppressive tumor microenvironment, such as inhibiting immunosuppressive cell populations (Tregs, MDSCs) or modulating the metabolic landscape
• Harnessing the gut microbiome to enhance the efficacy of immunotherapy, as the composition of the gut microbiota has been shown to influence patient response to ICIs
• Exploring the potential of combination therapies, such as combining different immunotherapies or integrating immunotherapy with targeted therapies, to improve patient outcomes
• Advancing personalized immunotherapy approaches based on individual patient characteristics, such as genetic profile, immune signature, and tumor microenvironment
• Investigating the role of epigenetic modulation in regulating anti-tumor immunity and developing epigenetic therapies to enhance immunotherapy efficacy
• Developing strategies to overcome the immunosuppressive effects of chronic viral infections, such as HIV and hepatitis B/C, on anti-tumor immunity in cancer patients
• Exploring the potential of immunotherapy in the prevention and treatment of early-stage cancers and precancerous lesions

Case Studies and Real-World Examples

• In a phase III clinical trial (CheckMate 067), the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) significantly improved overall survival in patients with advanced melanoma compared to either agent alone
• The CAR T cell therapy tisagenlecleucel (Kymriah) has shown remarkable efficacy in treating pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), with an overall remission rate of 81% in a pivotal clinical trial
• In the KEYNOTE-189 trial, the combination of pembrolizumab (anti-PD-1) with chemotherapy significantly improved overall survival and progression-free survival in patients with metastatic non-squamous NSCLC compared to chemotherapy alone
• The oncolytic virus talimogene laherparepvec (T-VEC) has been approved for the treatment of unresectable melanoma, demonstrating durable responses and improved overall survival in a phase III clinical trial
• In a case report, a patient with metastatic breast cancer experienced a complete response following treatment with a personalized neoantigen vaccine in combination with the PD-1 inhibitor pembrolizumab
• A phase I/II clinical trial investigating the combination of the IDO inhibitor epacadostat with pembrolizumab in patients with advanced solid tumors showed promising antitumor activity and a manageable safety profile
• In a retrospective analysis, patients with advanced melanoma who had a higher diversity of gut microbiota responded better to anti-PD-1 therapy, highlighting the potential role of the gut microbiome in modulating immunotherapy response
• A phase II clinical trial evaluating the efficacy of a dendritic cell vaccine loaded with personalized neoantigens in patients with newly diagnosed glioblastoma demonstrated promising survival outcomes and immunological responses